The global cancer immunotherapy market was valued at over USD 82.8 billion in 2021 and is projected to surpass USD 261.7 billion by the end of 2031, expanding at a robust CAGR of 13.6% from 2022 to 2031. Growth is driven by increasing cancer prevalence, rising adoption of advanced immunotherapy treatments such as checkpoint inhibitors and CAR-T cell therapies, and significant investments in oncology research. Additionally, ongoing clinical advancements and growing awareness of targeted and personalized therapies are expected to further accelerate market expansion over the forecast period.

Immunotherapy is a cancer treatment that improves the immune system’s ability to fight cancer. It is a kind of biological treatment. Biological therapy makes use of compounds derived from biological creatures or lab-created copies of these substances.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4312

Increase in R&D activities, improvements in efficacy & accuracy of newer medicines, surge in adoption of target therapy over standard therapy, and rise in prevalence of cancer are the major factors propelling the global cancer immunotherapy market. In addition, rise in incidence of cancer is a key factor driving the global cancer immunotherapy market. In the U.S., cancer is the biggest cause of mortality and disease, and it not only has a significant effect on the health of patients and survivors, but also has a major financial impact.

North America is projected to be a highly lucrative market for cancer immunotherapy during the forecast period. Well-established healthcare infrastructure and increase in government initiatives are the major factors driving the market in the region. North America’s large market share can be attributed to rise in number of patients suffering from cancer, increase in adoption rate of immunotherapy, and development of bioinformatics tools that enhance the drug development process.

Key Findings of the Market Report

• Based on product type, Monoclonal Antibodies lead in revenue, while Oncolytic Viral Therapies and Cancer Vaccines are identified as the fastest-growing lucrative segments.
• The Lung Cancer application accounts for the largest market share (~18.1%), driven by the high mortality rate and the success of PD-1 inhibitors in NSCLC.
• Hospitals and Clinics are the primary end-users (approx. 71.4% share), though specialized Cancer Research Centers are the focal point for emerging CAR-T and cellular therapies.
• Intravenous (IV) remains the standard route of administration, but the Subcutaneous segment (e.g., Roche’s Tecentriq Hybreza) is gaining traction for its significantly shorter administration time.

Global Market: Growth Drivers

• Rising Global Cancer Incidence: Estimates suggest new cases could reach 24.58 million annually by 2030, necessitating more sophisticated and long-term treatment solutions.
• Accelerated Regulatory Clearances: FDA and EMA “Fast Track” designations are shrinking the time-to-market for novel immuno-oncology drugs.
• Success of Checkpoint Inhibitors: The proven efficacy of drugs like Keytruda and Opdivo in extending 5-year survival rates for metastatic melanoma and lung cancer is driving massive recurring revenue.
• Expansion of Precision Medicine: AI-driven diagnostic tools are allowing for “personalized immunotherapy,” ensuring treatments are targeted to the specific genetic profile of a patient’s tumor.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4312

Global Market: Key Players

Market leaders are focusing on “ecosystem partnerships,” collaborating with diagnostic firms to bundle immunotherapy drugs with companion biomarkers.

• Merck & Co., Inc. (Keytruda)
• Bristol-Myers Squibb (Opdivo, Yervoy)
• F. Hoffmann-La Roche Ltd (Tecentriq)
• AstraZeneca plc (Imfinzi)
• Regeneron Pharmaceuticals, Inc. (Libtayo)
• Eli Lilly and Company
• Novartis AG (Kymriah)
• Gilead Sciences, Inc. (Yescarta)
• Johnson & Johnson (Darzalex)
• Akeso, Inc. (Ivonescimab)

Global Market: Segmentation

By Type

• Monoclonal Antibodies (mAbs)
• Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
• Cancer Vaccines
• Adoptive Cell Therapy (CAR-T)
• Immunomodulators
• Oncolytic Viral Therapies

By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head & Neck Cancer

By Route of Administration

• Intravenous (IV)
• Oral
• Subcutaneous
• Intramuscular

By End-User

• Hospitals and Clinics
• Cancer Research Centers
• Specialty Oncology Pharmacies

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=4312&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com